Table 3:
Quantitative benchmarks for clinical practice management
Characteristic | Value (%) [95% CI] |
---|---|
Percentage of initial BI-RADS 3 to total screens | 1,037/135,765 (0.76%) [ 0.72% - 0.81%] |
Percentage of initial BI-RADS 3 to screen-recalled (BI-RADS 0) cases | 1,037/13,453 (7.71%) [7.26% - 8.17%] |
Upgrade rate within 24 months of BI-RADS 3 | 77/1,037 (7.43%) [5.90% - 9.19%] |
PPV3 of biopsies within 24 months of BI-RADS 3 | 26/77 (33.77%) [23.38% - 45.45%] |
Cancer yield within 24 months of BI-RADS 3 | 26/1,037 (2.51%) [1.64% - 3.65%] |
Cancer type | |
Ductal carcinoma in situ (DCIS) | 12/26 (46.2%) [26.6% - 66.6%] |
Invasive ductal carcinoma (IDC) | 11/26 (42.3%) [23.4% - 63.1%] |
Invasive lobular carcinoma (ILC) | 3/26 (11.5%) [2.5% - 30.2%] |